검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Relmacabtagene Autoleucel (Autoleucel, Autoleucel (Relmacabtagene Autoleucel)) Sun Yat-sen University·Large B Cell Diffuse Lymphoma ORR 38% |
|---|---|
Overview Program | Autoleucel (Relmacabtagene Autoleucel) |
Overview Company | Sun Yat-sen University |
Overview Modality | CGT |
Overview Target | Large B Cell Diffuse Lymphoma |
Overview Indication | Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarkers of CAR-T cell expansion, we analyzed absolute lymphocyte count (ALC) as a surrogate biomarker in a |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Toxicology CRS | 4% |
Clinical Primary efficacy | ORR 38% |
Clinical ORR | 38.0% |
Clinical PFS | 3.5 |
Clinical OS | 9.6 |
Clinical Result source | ClinicalTrials.gov NCT05537766 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Relmacabtagene Autoleucel (Autoleucel, Autoleucel (Relmacabtagene Autoleucel)) Sun Yat-sen University·Large B Cell Diffuse Lymphoma ORR 38% |
|---|---|
Overview Program | Autoleucel (Relmacabtagene Autoleucel) |
Overview Company | Sun Yat-sen University |
Overview Modality | CGT |
Overview Target | Large B Cell Diffuse Lymphoma |
Overview Indication | Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarkers of CAR-T cell expansion, we analyzed absolute lymphocyte count (ALC) as a surrogate biomarker in a |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Toxicology CRS | 4% |
Clinical Primary efficacy | ORR 38% |
Clinical ORR | 38.0% |
Clinical PFS | 3.5 |
Clinical OS | 9.6 |
Clinical Result source | ClinicalTrials.gov NCT05537766 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교